Merck and Moderna’s intismeran autogene meets its primary endpoint in the Phase 3 INTerpath-001 trial in completely resected melanoma, Ultragenyx’s Genglycos receives FDA accelerated approval as the first treatment for glycogen storage disease type Ia, argenx’s efgartigimod meets its primary endpoint in the Phase 3 ALKIVIA trial in autoimmune myositis, Amylyx’s avexitide meets its primary endpoint in the Phase 3 LUCIDITY trial in post-bariatric hypoglycaemia, and EyePoint’s DURAVYU misses its primary endpoint in the Phase 3 LUGANO trial in wet age-related macular degeneration: the most significant clinical trial results 21 August 2026 has to offer from across the pipeline.
This week delivered an unusually favourable set of readouts spanning oncology, rare metabolic disease, neuromuscular autoimmunity, endocrinology and retinal medicine, with four of the five outcomes falling on the positive side of the ledger. The standout is the first successful late-stage trial of a cancer therapy built individually from the mutational signature of a patient’s own tumour, a result that answers a question the field has been asking for the better part of a decade. Around it sat a first-ever regulatory approval in an ultra-rare metabolic disorder, two late-stage successes in conditions where patients have relied on broad immunosuppression or on nothing at all, and a single missed primary endpoint whose interpretation now rests on an unplanned analysis. Here, Life Science Daily News brings you the week’s most significant readouts from across the pipeline.
Merck and Moderna’s Intismeran Autogene Meets Primary Endpoint in Phase 3 INTerpath-001 Melanoma Trial
Merck and Moderna announced on 19 August 2026 positive topline results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene, an investigational mRNA-based individualised neoantigen therapy also known as V940 or mRNA-4157, in combination with KEYTRUDA (pembrolizumab) as adjuvant treatment in patients with completely resected stage IIB to IV cutaneous melanoma. At a prespecified interim analysis, the combination met the primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival compared with KEYTRUDA alone. The companies describe the result as the first positive Phase 3 readout for an individualised neoantigen therapy and for an mRNA-based cancer therapy, and the first Phase 3 study to improve on KEYTRUDA alone in the adjuvant setting in resected melanoma. Safety profiles were consistent with previously reported studies of the combination, with no new safety signals.
INTerpath-001 enrolled 1,137 patients who, following complete surgical resection, were randomised 2:1 to intismeran at 1 mg every three weeks for up to nine doses plus KEYTRUDA at 400 mg every six weeks, or to KEYTRUDA alone, for approximately one year. Each therapy consists of synthetic mRNA coding for up to 34 neoantigens selected from the patient’s own tumour sample. No hazard ratios, medians or other effect sizes were disclosed, so the magnitude of benefit remains unknown until the data are presented; the trial continues in order to assess overall survival and other secondary endpoints. The readout builds on the Phase 2b KEYNOTE-942 study, whose five-year follow-up presented at the 2026 ASCO Annual Meeting showed a 49 per cent reduction in the risk of recurrence or death (HR 0.51; 95% CI 0.294 to 0.887). Merck and Moderna plan to present the data at an international medical meeting and to engage regulators on filing submissions.
FDA Approves Ultragenyx’s Genglycos as First Treatment for Glycogen Storage Disease Type Ia
Ultragenyx announced on 19 August 2026 that the FDA had granted accelerated approval to Genglycos (pariglasgene brecaparvovec-opnr), also known as DTX401, in adult and paediatric patients aged eight years and older with glycogen storage disease type Ia (GSDIa). The FDA confirmed it is the first approved treatment for the condition, an inherited disorder caused by deficiency of glucose-6-phosphatase in which patients cannot release stored glycogen as glucose and depend on an around-the-clock regimen of raw cornstarch to avoid life-threatening hypoglycaemia. Genglycos is a one-time AAV8-based gene therapy designed to deliver a functional G6PC gene to the liver. In the 48-week randomised, double-blind, placebo-controlled Phase 3 GlucoGene study, which treated 46 participants with gene therapy or placebo, treated patients achieved a statistically significant mean reduction from baseline in daily cornstarch intake of 31 per cent compared with placebo, the primary endpoint, alongside a mean reduction of one cornstarch dose per day on the secondary endpoint.
The terms of the approval deserve attention. The indication is to reduce daily cornstarch intake as an adjunct to nutritional management, and it rests on that surrogate rather than on a demonstrated reduction in hypoglycaemic events, with continued approval contingent on confirmatory work. The FDA also noted that treated patients experienced a numerical increase, of 3 per cent on average, in the percentage of glucose values falling in the hypoglycaemic range below 70 mg/dL compared with placebo. Ultragenyx has agreed to supply two years of safety and efficacy data from 50 commercially treated patients and 20 controls, the latter drawn from patients ineligible for treatment because of anti-AAV8 antibodies, through a disease monitoring programme running for ten years. The safety profile is substantial: the therapy is contraindicated in known severe hepatic fibrosis or cirrhosis and carries warnings covering anaphylaxis, liver toxicity, adrenal insufficiency and a theoretical risk of tumorigenicity. Seven serious adverse events occurred during the primary efficacy analysis period, and elevated ALT or AST was reported in 71 per cent of treated patients. GSDIa affects an estimated 1,500 to 2,500 people in the United States.
argenx’s Efgartigimod Meets Primary Endpoint in Phase 3 ALKIVIA Trial in Autoimmune Myositis
argenx announced on 17 August 2026 positive topline results from the Phase 3 portion of ALKIVIA, evaluating VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis. In the combined immune-mediated necrotising myopathy (IMNM) and dermatomyositis (DM) population, patients receiving efgartigimod showed a 15.4-point greater improvement in mean Total Improvement Score at week 52 than placebo (47.95 versus 32.56, p=0.0011). Separation from placebo emerged at week 4 and was sustained through a full year of treatment despite a protocol-mandated corticosteroid taper. All six core set measures contributing to the Total Improvement Score favoured efgartigimod in both subtypes, spanning muscle strength, everyday physical function and disease activity beyond the muscle. argenx reported the drug as well tolerated, with a safety profile consistent with prior studies.
The subtype analyses are where the result becomes more qualified. In prespecified analyses, the primary endpoint was met in IMNM patients (p=0.0048), with a 14.8-point greater improvement over placebo (45.05 versus 30.24). In DM, a comparable 14.5-point improvement was observed (51.51 versus 36.96), but statistical significance was not reached in this smaller cohort (p=0.1093). argenx’s claim that these are the first Phase 3 results to show statistically significant improvement in IMNM, a subtype with no approved therapy, therefore stands on the IMNM analysis, while the DM finding rests on effect magnitude rather than on a significant p-value. ALKIVIA was an operationally seamless Phase 2/3 study spanning IMNM, DM and polymyositis, enrolling 264 patients in total with 175 in the Phase 3 portion; no result was reported for the polymyositis cohort. Approximately 100,000 people in the United States live with autoimmune myositis, including roughly 20,000 with IMNM. Detailed results will be presented at an upcoming medical meeting.
Amylyx’s Avexitide Meets Primary Endpoint in Phase 3 LUCIDITY Trial in Post-Bariatric Hypoglycaemia
Amylyx announced on 18 August 2026 positive topline results from LUCIDITY, a multicentre, randomised, double-blind, placebo-controlled Phase 3 trial of avexitide, an investigational GLP-1 receptor antagonist that Amylyx describes as first-in-class, in participants with post-bariatric hypoglycaemia (PBH) following Roux-en-Y gastric bypass surgery. The trial met the FDA-agreed primary endpoint, with a 55 per cent reduction in the composite rate of Level 2 and Level 3 hypoglycaemic events compared with placebo through week 16 (p=0.000003). All secondary endpoints were also met, with reductions across Level 2 events measured by self-monitoring of blood glucose, Level 2 events measured by continuous glucose monitoring, and independently adjudicated Level 3 events. There are currently no FDA-approved therapies for PBH.
LUCIDITY enrolled 78 adults across 21 sites in the United States, randomised 3:2 to 90 mg of avexitide subcutaneously once daily or to placebo, with a 16-week double-blind treatment period followed by a 32-week open-label extension that remains ongoing. Amylyx reported avexitide as generally well tolerated, with most adverse events mild to moderate and no serious adverse events related to treatment; the most common were diarrhoea and injection site erythema and bruising. No change in body weight was observed in either arm. In PBH, an exaggerated GLP-1 response drives excessive insulin secretion, and avexitide is designed to block that response at the receptor. The condition is estimated to affect around 8 per cent of people in the United States who have undergone the two most common bariatric procedures, roughly 160,000 people. Amylyx plans to submit a New Drug Application by the end of 2026; avexitide holds Breakthrough Therapy and Orphan Drug designations.
EyePoint’s DURAVYU Misses Primary Endpoint in Phase 3 LUGANO Trial in Wet AMD
EyePoint announced on 17 August 2026 topline data from LUGANO, the first of two pivotal Phase 3 trials of DURAVYU (vorolanib intravitreal insert) in wet age-related macular degeneration. The primary endpoint, change from baseline in best corrected visual acuity at weeks 52 and 56 against on-label 2 mg aflibercept, was not achieved in the full dataset. The company reported non-inferiority to aflibercept (nominal p=0.0096) in an ad hoc analysis that excluded a cohort of nine of 211 patients who lost 15 or more letters, which EyePoint attributes to causes unrelated to wet AMD. No patients in the aflibercept arm experienced comparable loss, and the company argues that the control arm outperformed the 3 to 5 per cent rate of such loss seen in previously reported trials of similar scale, a cross-trial comparison rather than a like-for-like one, and that this contributed to the primary endpoint result.
Secondary endpoints were considerably stronger, though the p-values reported are nominal throughout. DURAVYU delivered a 42 per cent reduction in treatment burden against on-label aflibercept (nominal p<0.0001), equivalent to two fewer injections on average through week 56, against a maximum possible reduction of 60 per cent. Fifty-four per cent of DURAVYU patients were free of supplemental injections to week 56 and 79 per cent received no more than one, and a prespecified analysis in supplement-free patients showed non-inferiority in visual acuity (nominal p=0.0035). Anatomic control was close to the comparator, with a mean difference of 4 microns in central subfield thickness at week 56, and EyePoint reported the insert as safe and well tolerated with repeat dosing. President and Chief Executive Jay S. Duker described the full-dataset primary endpoint result as unexpected. Topline data from the second pivotal trial, LUCIA, are due in the fourth quarter of 2026, with a potential FDA filing in the first half of 2027 contingent on that outcome.
Looking Ahead
This week’s clinical trial results 21 August 2026 mark one of the more encouraging stretches of the year, and the two firsts within it are of very different kinds. The melanoma readout is the more consequential in scientific terms, because it converts a long-running bet on individualised mRNA therapy into a positive late-stage result, though the absence of any disclosed effect size means the size of that win cannot yet be judged. The gene therapy approval in glycogen storage disease type Ia gives a small community its first targeted option after decades without one, with the important qualification that it was granted on a surrogate measure of daily care burden and carries a demanding safety profile. In autoimmune myositis and post-bariatric hypoglycaemia, two conditions long managed with blunt tools or none at all, late-stage evidence now exists for targeted mechanisms, although one of those results holds statistically in only one subtype. The retinal miss is the week’s cautionary note, and how much weight the unplanned analysis can bear will be settled by the second pivotal trial rather than by argument. Catch up on our previous clinical trials roundup. Life Science Daily News will continue to bring you accurate, timely coverage of the clinical trial results that matter most across the global life sciences pipeline.
